Assessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity Investment [Yahoo! Finance]
Sana Biotechnology, Inc. (SANA)
Company Research
Source: Yahoo! Finance
Sana Biotechnology (SANA) is back in focus after Mayo Clinic agreed to collaborate on SC451 for type 1 diabetes and invest up to US$50 million, linking clinical expertise with fresh capital support. See our latest analysis for Sana Biotechnology. The Mayo Clinic collaboration and recent equity raises have arrived alongside a 7.3% 7 day share price return and an 18.3% 30 day share price return, while the 1 year total shareholder return is very large. This suggests that momentum has picked up after earlier weakness. If this type of medical breakthrough story interests you, it may be worth looking across the wider healthcare and AI space through our screener of 35 healthcare AI stocks With Sana trading at US$3.69 and analysts' average price target sitting higher, plus Mayo Clinic committing fresh capital, the key question is whether the current valuation still leaves room for upside or already reflects future growth. Preferred Price to Book of 6.3x: Is it justified? Sana tra
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- Sana Biotechnology (SANA) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Sana Biotechnology: Mayo Clinic Deal A Positive Step On A Long Journey [Seeking Alpha]Seeking Alpha
- Sana Biotechnology (SANA) had its "outperform" rating reaffirmed by Wedbush.MarketBeat
- Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451GlobeNewswire
- Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
SANA
Earnings
- 8/11/25 - Beat
SANA
Sec Filings
- 4/13/26 - Form 424B5
- 4/13/26 - Form 8-K
- 4/8/26 - Form 4
- SANA's page on the SEC website